Sort
10,766 grants matching “checkpoint inhibitor”
THE ROLE OF GADD45 IN G2 - M CHECKPOINT
$210,291University Of Pittsburgh At Pittsburgh · R01 · FY2002 · CA
A high-throughput screen for inhibitors of Plk1-interacting checkpoint helicase (PICH)
$210,153Duncan J Clarke · University Of Minnesota · R21 · FY2023 · CA
Development Therapeutics Branch Clinical Trials
$210,145Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients
$210,000Dori A Thomas-Karyat · Synthis Therapeutics, Inc. · R43 · FY2020 · CA
Nitric oxide immune dependent resistance mechanisms to anti-PD-1 therapy
$209,852Joseph Markowitz · H. Lee Moffitt Cancer Ctr & Res Inst · K08 · FY2023 · CA
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
$209,850Edward B Garon · University Of California Los Angeles · R21 · FY2024 · CA
Next-Generation Antibody Discovery and Development Technology
$209,825David Scott Johnson · Gigagen, Inc. · R44 · FY2018 · CA
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities
$209,670Brent Allen Hanks · Duke University · R01 · FY2024 · CA
Therapeutic targeting of VHL-deficient clear cell renal cell carcinoma
$209,646Olga V Razorenova · University Of California-Irvine · R21 · FY2025 · CA
Preclinical development of CXCR6 antagonists to target sorafenib resistance in Hepatocellular Carcinoma
$209,604Siobhan Malany · University Of Florida · R21 · FY2023 · CA
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
$209,500Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · U54 · FY2024 · CA
Advancing Bladder Cancer Care by Imaging and Intravesical Immune Checkpoint Blockade
$209,468Pradeep Tyagi · University Of Pittsburgh At Pittsburgh · R21 · FY2022 · CA
Naïve T cell archetypes and anti-tumor immunity
$209,375Carla Rothlin · Yale University · R21 · FY2024 · AI
Development of BBB Permeable PD-L1 PET Imaging Agents
$209,375Zhengxin Cai · Yale University · R21 · FY2020 · EB
Early Detection and Immunomodulation of PD-1 Inhibitor Induced Cardiotoxicity
$209,275Saraswati Pokharel · Roswell Park Cancer Institute Corp · R21 · FY2021 · HL
Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly
$209,150Suzanne Marie Ponik · University Of Wisconsin-Madison · R21 · FY2022 · CA
Project 2 - Joshua Hood, PhD
$209,089Joshua L. Hood · University Of Louisville · P20 · FY2023 · GM
Mechanisms of anti-tumor activity of group A Streptococcus in pancreatic adenocarcinoma
$208,916Brian A Boone · West Virginia University · R21 · FY2023 · CA
Exploiting the immune microenvironment for radiotargeted destruction of leptomeningeal metastases
$208,865Radu Minea · University Of Southern California · R21 · FY2019 · CA
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
$208,829Tao Zou · Dana-Farber Cancer Inst · K08 · FY2021 · CA
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
$208,829Tao Zou · Dana-Farber Cancer Inst · K08 · FY2025 · CA
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
$208,829Tao Zou · Dana-Farber Cancer Inst · K08 · FY2023 · CA
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
$208,829Tao Zou · Dana-Farber Cancer Inst · K08 · FY2022 · CA
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
$208,829Tao Zou · Dana-Farber Cancer Inst · K08 · FY2024 · CA
Targeting Tankyrases to Mitigate Immunosuppression and Enhance Cancer Immunotherapy
$208,800Steven Hsesheng Lin · University Of Tx Md Anderson Can Ctr · R21 · FY2019 · CA